687 related articles for article (PubMed ID: 9664134)
1. A new mouse model of experimental melanoma for vaccine and lymphokine therapy.
Shrayer DP; Bogaars H; Wolf SF; Hearing VJ; Wanebo HJ
Int J Oncol; 1998 Aug; 13(2):361-74. PubMed ID: 9664134
[TBL] [Abstract][Full Text] [Related]
2. Immunization of mice with irradiated melanoma tumor cells transfected to secrete lymphokines and coupled with IL-2 or GM-CSF therapy.
Shrayer DP; Bogaars H; Hearing VJ; Wanebo HJ
J Exp Ther Oncol; 1996 Mar; 1(2):126-33. PubMed ID: 9414396
[TBL] [Abstract][Full Text] [Related]
3. Novel membrane-bound GM-CSF vaccines for the treatment of cancer: generation and evaluation of mbGM-CSF mouse B16F10 melanoma cell vaccine.
Yei S; Bartholomew RM; Pezzoli P; Gutierrez A; Gouveia E; Bassett D; Soo Hoo W; Carlo DJ
Gene Ther; 2002 Oct; 9(19):1302-11. PubMed ID: 12224013
[TBL] [Abstract][Full Text] [Related]
4. Combined vaccination with major histocompatibility class I and interleukin 2 gene-transduced melanoma cells synergizes the cure of postsurgical established lung metastases.
Porgador A; Tzehoval E; Vadai E; Feldman M; Eisenbach L
Cancer Res; 1995 Nov; 55(21):4941-9. PubMed ID: 7585534
[TBL] [Abstract][Full Text] [Related]
5. Granulocyte-macrophage colony-stimulating factor and interleukin-2 fusion cDNA for cancer gene immunotherapy.
Stagg J; Wu JH; Bouganim N; Galipeau J
Cancer Res; 2004 Dec; 64(24):8795-9. PubMed ID: 15604233
[TBL] [Abstract][Full Text] [Related]
6. Xenogeneic DNA immunization in melanoma models for minimal residual disease.
Hawkins WG; Gold JS; Blachere NE; Bowne WB; Hoos A; Lewis JJ; Houghton AN
J Surg Res; 2002 Feb; 102(2):137-43. PubMed ID: 11796010
[TBL] [Abstract][Full Text] [Related]
7. Preclinical evaluation of "whole" cell vaccines for prophylaxis and therapy using a disabled infectious single cycle-herpes simplex virus vector to transduce cytokine genes.
Ali SA; McLean CS; Boursnell ME; Martin G; Holmes CL; Reeder S; Entwisle C; Blakeley DM; Shields JG; Todryk S; Vile R; Robins RA; Rees RC
Cancer Res; 2000 Mar; 60(6):1663-70. PubMed ID: 10749137
[TBL] [Abstract][Full Text] [Related]
8. Granulocyte-macrophage colony-stimulating factor (GM-CSF) secreted by cDNA-transfected tumor cells induces a more potent antitumor response than exogenous GM-CSF.
Shi FS; Weber S; Gan J; Rakhmilevich AL; Mahvi DM
Cancer Gene Ther; 1999; 6(1):81-8. PubMed ID: 10078967
[TBL] [Abstract][Full Text] [Related]
9. Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha1,3galactosyltransferase.
LaTemple DC; Abrams JT; Zhang SY; Galili U
Cancer Res; 1999 Jul; 59(14):3417-23. PubMed ID: 10416604
[TBL] [Abstract][Full Text] [Related]
10. Effect of irradiation on cytokine production, MHC antigen expression, and vaccine potential of interleukin-2 and interferon-gamma gene-modified melanoma cells.
Abdel-Wahab Z; Dar MM; Hester D; Vervaert C; Gangavalli R; Barber J; Darrow TL; Seigler HF
Cell Immunol; 1996 Aug; 171(2):246-54. PubMed ID: 8806794
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic efficacy of antigen-specific vaccination and toll-like receptor stimulation against established transplanted and autochthonous melanoma in mice.
Tormo D; Ferrer A; Bosch P; Gaffal E; Basner-Tschakarjan E; Wenzel J; Tüting T
Cancer Res; 2006 May; 66(10):5427-35. PubMed ID: 16707471
[TBL] [Abstract][Full Text] [Related]
12. Lymphotactin cotransfection enhances the therapeutic efficacy of dendritic cells genetically modified with melanoma antigen gp100.
Xia DJ; Zhang WP; Zheng S; Wang J; Pan JP; Wang Q; Zhang LH; Hamada H; Cao X
Gene Ther; 2002 May; 9(9):592-601. PubMed ID: 11973635
[TBL] [Abstract][Full Text] [Related]
13. Anti-tumour activity against B16-F10 melanoma with a GM-CSF secreting allogeneic tumour cell vaccine.
Kayaga J; Souberbielle BE; Sheikh N; Morrow WJ; Scott-Taylor T; Vile R; Chong H; Dalgleish AG
Gene Ther; 1999 Aug; 6(8):1475-81. PubMed ID: 10467372
[TBL] [Abstract][Full Text] [Related]
14. Antigens and cytokine genes in antitumor vaccines: the importance of the temporal delivery sequence in antitumor signals.
Herrero MJ; Botella R; Dasí F; Algás R; Sánchez M; Aliño SF
Ann N Y Acad Sci; 2006 Dec; 1091():412-24. PubMed ID: 17341632
[TBL] [Abstract][Full Text] [Related]
15. Vaccination with B16 melanoma cells expressing a secreted form of interleukin-1beta induces tumor growth inhibition and an enhanced immunity against the wild-type B16 tumor.
Björkdahl O; Dohlsten M; Sjögren HO
Cancer Gene Ther; 2000 Oct; 7(10):1365-74. PubMed ID: 11059695
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic efficacy of T cells derived from lymph nodes draining a poorly immunogenic tumor transduced to secrete granulocyte-macrophage colony-stimulating factor.
Arca MJ; Krauss JC; Aruga A; Cameron MJ; Shu S; Chang AE
Cancer Gene Ther; 1996; 3(1):39-47. PubMed ID: 8785710
[TBL] [Abstract][Full Text] [Related]
17. Induction of anti-tumor immunity by vaccination with dendritic cells pulsed with anti-CD44 IgG opsonized tumor cells.
Pilon-Thomas S; Verhaegen M; Kuhn L; Riker A; Mulé JJ
Cancer Immunol Immunother; 2006 Oct; 55(10):1238-46. PubMed ID: 16315029
[TBL] [Abstract][Full Text] [Related]
18. Recombinant vaccinia virus expressing cytokine GM-CSF as tumor vaccine.
Chatterjee SK; Qin H; Manna S; Tripathi PK
Anticancer Res; 1999; 19(4B):2869-73. PubMed ID: 10652566
[TBL] [Abstract][Full Text] [Related]
19. Antitumor effect on murine renal cell carcinoma by autologous tumor vaccines genetically modified with granulocyte-macrophage colony-stimulating factor and interleukin-6 cells.
Kinoshita Y; Kono T; Yasumoto R; Kishimoto T; Wang CY; Haas GP; Nishisaka N
J Immunother; 2001; 24(3):205-11. PubMed ID: 11394497
[TBL] [Abstract][Full Text] [Related]
20. Eradication of melanoma pulmonary metastases by immunotherapy with tumor cells engineered to secrete interleukin-2 or gamma interferon.
Abdel-Wahab Z; Dar M; Osanto S; Fong T; Vervaert CE; Hester D; Jolly D; Seigler HF
Cancer Gene Ther; 1997; 4(1):33-41. PubMed ID: 9012449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]